Gastroenterology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Procter & Gamble and ARYx investigate treatment for gastrointestinal disorders
August 7th, 2006
Procter & Gamble Pharmaceuticals, Inc., a division of The Procter & Gamble Company (PG) and ARYx Therapeutics announced a strategic alliance under which P&G will develop and commercialize ARYx's novel drug, ATI-7505, for the treatment of gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and gastroparesis. ATI-7505 is an oral, serotonin type 4 (5HT4) agonist that is in Phase development. It has been shown to have prokinetic properties (increases upper GI motility, which is believed to play a beneficial role in GI symptom reduction). Based on its mechanism of action, initial studies show that ATI- 7505 prevents the regurgitation...
Source: Gastroenterology Week (2006-08-07)
|
